MediciNova, Inc.: MediciNova Announces Patient Enrollment Milestone Achieved in SEANOBI Study Expanded-Access-Program Evaluating MN-166 (ibudilast) in ALS patients
MediciNova (NASDAQ: MNOV) said it reached enrollment of 200 patients in the NIH-funded SEANOBI-ALS expanded-access study (NCT 06743776) evaluating MN-166 (ibudilast) in ALS. The program is for patients not eligible for randomized trials. Final follow-ups are expected to finish in early 2027 for data analysis and presentations.
How this was made
The 30-second read
Why it matters
Reaching the 200-patient enrollment target is a program-execution milestone that can improve confidence in ongoing protocol follow-ups and future data analysis/presentation timelines.
Market read
This is a concrete, time-stamped enrollment milestone for MN-166’s ALS expanded-access program, with follow-ups expected to finish in early 2027.
What to watch
Key catalysts remain later, including the early-2027 follow-up completion and any subsequent analyses or presentations; the article does not quantify biomarker outcomes or adverse events.
Background
SEANOBI-ALS is an NIH/NINDS ACT for ALS-funded expanded-access program providing MN-166 (ibudilast) to ALS patients not eligible for randomized trials.
Ticker impact
MediciNova says SEANOBI-ALS expanded-access enrollment hit the 200-patient target, with final follow-ups projected to end in early 2027.
Near-term upside bias possible on improved program execution, but magnitude likely limited versus randomized Phase 3 readouts.
The milestone is concrete and time-bound, but it is expanded-access (not efficacy trial results) and the article provides no new efficacy or safety datapoints.
Market effects
Supports sentiment for ALS neuroinflammation programs and for PDE4 inhibitor MN-166 as an active clinical-development candidate.
Limited direct regional impact; company is US-listed with Tokyo secondary listing.
ALS community engagement and NIH ACT for ALS funding reinforce US-led translational research momentum.
Counterpoint
Expanded-access enrollment completion may not translate into commercial or regulatory value without efficacy signals; investors may discount it versus Phase 3 outcomes.
Key entities
- companyMediciNova, Inc.
NASDAQ-listed biopharmaceutical company developing MN-166 (ibudilast) for ALS and other neurodegenerative indications.
- drugMN-166 (ibudilast)
Orally available PDE4 and inflammatory cytokine inhibitor being evaluated in ALS and other indications.
- clinical_programSEANOBI-ALS (NCT 06743776)
Expanded-access study evaluating MN-166 in ALS patients, with target enrollment of 200.
- funderNINDS/NIH ACT for ALS
US government support for the expanded-access program.
